Richard Meyer

GLP-1 drugs are real medical breakthroughs. The "GLP-1 economy" is the exaggerated part. Yes, adoption is rising. KFF found that 18% of U.S. adults had ever taken a GLP-1 by late 2025, and 12% were currently taking one. That is meaningful, but it also means nearly 9 in 10 adults were not current users. ( KFF) That distinction matters. The U.S. economy is not transformed by anecdotes about Ozempic users skipping dessert. It is transformed when behavior changes at population scale. We are not there.

As healthcare becomes increasingly complex and digital transformation reshapes the industry, pharma marketing professionals play a critical role in helping innovative treatments reach the people who need them most. However, it's not without frustration, but those willing to "navigate and challenge" the system can have a very rewarding career.

Medical Science Liaisons (MSLs) serve as a critical bridge between pharmaceutical and biotechnology companies and the medical community. A common question within the life sciences industry is: Do physicians actually like working with MSLs? The short answer is: many physicians do-but only when MSLs deliver genuine scientific value and don't bow to commercial leaders.